P1VITAL LIMITED

Their core work

P1Vital is a UK-based SME specializing in experimental medicine and clinical biomarker services for psychiatric and neurological disorders. They develop predictive tools and biological markers to determine which patients will respond to specific treatments — particularly for depression, schizophrenia, and Alzheimer's disease. Their core business is running biomarker-driven clinical studies that help pharmaceutical companies and researchers stratify patients and predict treatment outcomes, reducing the cost and failure rate of CNS drug development.

What they specialise in

How they've shifted over time

P1Vital's early H2020 work (2015-2019) concentrated squarely on predicting treatment response in depression, where they led the PReDicT project through both SME Instrument phases. Their more recent participation (2021-2024) shows a broadening into transdiagnostic psychiatry — covering schizophrenia and Alzheimer's alongside depression — and a shift toward digital biomarkers and quantitative biology methods. This evolution suggests a company moving from a single-indication focus toward becoming a broader CNS biomarker platform.

P1Vital is expanding from depression-specific prediction tools toward a broader transdiagnostic, digitally-enabled biomarker platform covering multiple CNS conditions including neurodegeneration.

How they like to work

P1Vital balances leadership and partnership roles evenly — they coordinated their own flagship PReDicT project (winning both SME-1 and SME-2 funding, a notable achievement) while contributing specialist biomarker expertise to the large IMI2 PRISM consortia. With 29 unique partners across 9 countries, they operate comfortably in both small focused teams and large public-private partnerships. Their IMI2 participation signals credibility with major pharmaceutical companies, who are typically co-funders in such projects.

P1Vital has built a network of 29 partners across 9 countries, with strong ties to both academic institutions and pharmaceutical companies through IMI2 consortia. Their geographic spread across Europe reflects the broad, multi-country nature of CNS clinical research collaborations.

What sets them apart

P1Vital occupies a rare niche as a specialized SME that bridges pharmaceutical drug development and academic neuroscience through predictive biomarker services. Their successful progression through both SME Instrument phases for PReDicT demonstrates commercial viability, while their role in IMI2 projects shows they are trusted by large pharma as a credible clinical partner. For consortium builders, they offer something hard to find: a small, agile company with deep expertise in CNS patient stratification and practical experience running biomarker-driven clinical studies.

Highlights from their portfolio

• PReDicT
  Successfully progressed from SME-1 feasibility (€50K) to SME-2 scale-up (€4.1M) — one of the competitive SME Instrument success stories in psychiatric medicine.
• PRISM 2
  Continuation of a major IMI2 public-private partnership tackling transdiagnostic psychiatry with digital biomarkers, spanning Alzheimer's, schizophrenia, and depression.